In addition to its clinical relevance, further exploration of TNFR2-targeted therapies and longitudinal studies investigating the long-term impact of TNFR2 modulation may provide valuable insights into improving outcomes and management strategies for patients with MGN. Here, TNFRSF1B is linked to idiopathic membranous glomerulonephritis.